update New Research Shows NuvaRing Significantly Raises Risk of Heart Problems and Stroke

RLG, which represents clients with claims stemming from the adverse effects of the birth control device known as NuvaRing, is helping to publicize new research showing that the use of birth control that, like NuvaRing, combines estrogen and progestin, significantly increases a woman’s risk of heart attack and stroke.

Published June 14 in the New England Journal of Medicine, the report is based on Danish researchers’ review of 15 years of observational data from more than 1.6 million women aged 15 to 49. Led by Dr. Ojvind Lidegaard, a clinical professor of obstetrics and gynecology at the Copenhagen hospital Rigshospitalet, the researchers found that the female subjects taking “low-dose estrogen birth control pills combined with various progestins suffered heart attacks and strokes between 1.5 and 2 times more often than women not using hormonal contraception,” the article states. “The risks were between 2.5 and 3 times higher among users of vaginal rings and transdermal patches compared to non-users.”

As a law firm that represents many women alleging serious injury as a result of having taken NuvaRing, the Rottenstein Law Group takes measures to alert consumers about the dangers posed by birth control devices, medical implants and dangerous drugs. The firm’s NuvaRing Lawsuit Information Center describes all of the issues that NuvaRing users face and explains their options.

Join the Discussion

Please note: Comments are encouraged in order to permit visitors to discuss relevant topics. Comments are moderated and might be edited by RLG before being published.

Comments should not be used to ask questions of RLG’s lawyers; if you want to speak with a lawyer, please fill out this contact form or call 1 (888) 976-8529. *Your name and email address will not be published.

*


× 9 = fifty four

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

RLG encourages you to reproduce our original content—on your own web site; in emails to your friends and family; in blogs, posts, and tweets, etc.—but we ask that you please attribute whatever you use to us, and, whenever possible, provide a link to the page where you first found the material. That way, whoever reads your excerpt might read more informative material of interest at one of RLG's sites.
You’ve taken enough. We'll take it from here. Click here to contact us now.